Home Cart Sign in  
Chemical Structure| 289483-69-8 Chemical Structure| 289483-69-8

Structure of E7820
CAS No.: 289483-69-8

Chemical Structure| 289483-69-8

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

E7820 (ER68203-00) is an orally active aromatic sulfonamide derivative and a unique angiogenesis inhibitor that inhibits the expression of integrin alpha2 subunit on endothelial cells. E7820 inhibits rat aortic angiogenesis with an IC50 of 0.11 μg/ml. E7820 modulates the mRNA expression of α-1, α-2, α-3, and α-5 integrins. It possesses anti-angiogenic and anti-tumor activities.

Synonyms: ER68203-00

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of E7820

CAS No. :289483-69-8
Formula : C17H12N4O2S
M.W : 336.37
SMILES Code : O=S(C1=CC=CC(C#N)=C1)(NC2=CC=C(C)C3=C2NC=C3C#N)=O
Synonyms :
ER68203-00
MDL No. :MFCD09833234
InChI Key :LWGUASZLXHYWIV-UHFFFAOYSA-N
Pubchem ID :196970

Safety of E7820

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P280-P301+P312-P302+P352-P305+P351+P338

Related Pathways of E7820

cytoskeleton

Isoform Comparison

Biological Activity

Description
E7820 (ER68203-00), an orally active aromatic sulfonamide derivative, is a unique angiogenesis inhibitor that suppresses the expression of the integrin alpha2 subunit on endothelial cells. It inhibits angiogenesis in rat aorta with an IC50 of 0.11 µg/ml and affects the expression of α-1, α-2, α-3, and α-5 integrin mRNA. E7820 displays antiangiogenic and antitumor activity[1][2].

In Vitro:

Cell Line
Concentration Treated Time Description References
HUVECs 50 ng/ml 17 hours E7820 decreased integrin α2 expression in HUVECs BMC Cancer. 2021 May 18;21(1):571
MC3T3 cells 50 ng/ml 17 hours E7820 increased integrin α2 expression in MC3T3 cells BMC Cancer. 2021 May 18;21(1):571
H1650 cells 3 μM 96 hours To evaluate the effect of E7820 in combination with erlotinib on proliferation and apoptosis of H1650 cells. Results showed that the combination significantly inhibited H1650 cell growth and enhanced apoptosis. Cancer Sci. 2014 Aug;105(8):1023-31
H1975 cells 3 μM 96 hours To evaluate the effect of E7820 in combination with erlotinib on proliferation and apoptosis of H1975 cells. Results showed that the combination did not significantly inhibit H1975 cell growth or induce apoptosis. Cancer Sci. 2014 Aug;105(8):1023-31
A549 cells 3 μM 96 hours To evaluate the effect of E7820 in combination with erlotinib on proliferation and apoptosis of A549 cells. Results showed that the combination did not significantly inhibit A549 cell growth or induce apoptosis. Cancer Sci. 2014 Aug;105(8):1023-31
HUVECs 3 μM 48 hours To evaluate the effect of E7820 in combination with erlotinib on proliferation and apoptosis of HUVECs. Results showed that the combination significantly inhibited HUVEC growth and enhanced apoptosis. Cancer Sci. 2014 Aug;105(8):1023-31
eEnd2 cells 50 ng/ml 17 hours E7820 did not significantly alter integrin α2 expression in eEnd2 cells BMC Cancer. 2021 May 18;21(1):571
Saos-2 cells 50 ng/ml 17 hours E7820 did not significantly alter integrin α2 expression in Saos-2 cells BMC Cancer. 2021 May 18;21(1):571
DLD1-KO (BRCA2 knockout) 1 µM 72 hours Evaluate DNA double-strand break induction and sensitivity of E7820 in BRCA2-deficient cells. Results showed significant γH2AX induction and RBM39 degradation in DLD1-KO cells with higher sensitivity than parental cells. NPJ Precis Oncol. 2024 May 24;8(1):117
HCT116 cells 1 μM 12 hours E7820 suppressed ARNT levels and promoted proteasomal degradation of ARNT through interaction with DCAF15. Mol Cells. 2020 Nov 30;43(11):935-944
HEK293T cells 1 μM 12 hours E7820 suppressed ARNT levels and promoted proteasomal degradation of ARNT through interaction with DCAF15. Mol Cells. 2020 Nov 30;43(11):935-944
Kelly cells 10 μM 5 hours To evaluate the degradation effect of E7820 on RBM39 and RBM23 Nat Chem Biol. 2020 Jan;16(1):7-14
NCI-H1299 cells 1 µM 72 hours Suppressed MTX-induced EMT-related phenotypic changes, such as morphology and mRNA and protein expression of α-smooth muscle actin Toxicol Res. 2022 Mar 16;38(4):449-458
A549 cells 1 µM 72 hours Suppressed MTX-induced EMT-related phenotypic changes, such as morphology and mRNA and protein expression of α-smooth muscle actin Toxicol Res. 2022 Mar 16;38(4):449-458

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
NOG mice Patient-derived xenograft (PDX) models Oral 100 mg/kg or 200 mg/kg Daily for 21 days Evaluate antitumor efficacy of E7820 in diverse solid tumor PDX models. Overall response rate was 38.1% (16/42), with highest sensitivity in bile duct cancer (58.3%). Loss-of-function mutations in HRR genes (e.g., ATM) significantly correlated with sensitivity (p=4.5×10^-3). NPJ Precis Oncol. 2024 May 24;8(1):117
Nude mice Non-small-cell lung cancer xenograft models Oral E7820: 25 or 50 mg/kg; erlotinib: 60 mg/kg E7820: twice daily; erlotinib: once daily; for 3 weeks To evaluate the antitumor activity of E7820 in combination with erlotinib in EGFR-TKI-resistant non-small-cell lung cancer xenograft models. Results showed that the combination exhibited a synergistic antitumor effect in three xenograft models, significantly decreasing microvessel density and increasing apoptosis of tumor-associated endothelial cells. Cancer Sci. 2014 Aug;105(8):1023-31

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT05024994 Acute Myeloid Leukemia|Myelody... More >>splastic Syndromes|Chronic Myelomonocytic Leukemia Less << PHASE2 ACTIVE_NOT_RECRUITING 2025-08-25 University of Miami (Data Coll... More >>ection AND Specimen Analysis Only), Miami, Florida, 33136, United States|Memorial Sloan Kettering Basking Ridge, Basking Ridge, New Jersey, 07920, United States|Memorial Sloan Kettering Monmouth, Middletown, New Jersey, 07748, United States|Memorial Sloan Kettering Bergen, Montvale, New Jersey, 07645, United States|Memorial Sloan Kettering Commack, Commack, New York, 11725, United States|Memorial Sloan Kettering Westchester (All protocol activities), Harrison, New York, 10604, United States|Memorial Sloan Kettering Nassau, Uniondale, New York, 11553, United States Less <<
NCT00078637 Neoplasms|Lymphoma, Malignant PHASE1 COMPLETED 2025-02-07 San Antonio, Texas, United Sta... More >>tes Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.97mL

0.59mL

0.30mL

14.86mL

2.97mL

1.49mL

29.73mL

5.95mL

2.97mL

References

 

Historical Records

Categories